Nilotinib monohydrochloride monohydrate is a potent tyrosine kinase inhibitor primarily indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. By selectively inhibiting… Read more
Nilotinib monohydrochloride monohydrate is a potent tyrosine kinase inhibitor primarily indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. By selectively inhibiting the Bcr-Abl tyrosine kinase, the drug effectively controls cell proliferation and disease progression in patients. This category provides access to high-quality reference standards, including the active pharmaceutical ingredient, its related impurities, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these materials for rigorous impurity profiling, method validation, and routine quality control testing. By incorporating these precise analytical standards into assay development, researchers can ensure accurate quantification and regulatory compliance during the production and stability testing of the drug substance. Whether performing forced degradation studies or routine batch release, these compounds support the analytical requirements necessary for maintaining the efficacy and safety standards of pharmaceutical products.
